REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Radical -xh Acid, Or Anhydride, Acid Halide Or Salt Thereof (x Is Chalcogen) Doai > Carboxylic Acid, Percarboxylic Acid, Or Salt Thereof (e.g., Peracetic Acid, Etc.) > Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Nitrogen Other Than As Nitro Or Nitroso Nonionically BondedNitrogen Other Than As Nitro Or Nitroso Nonionically Bonded patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027212 - Alpha 2 delta ligands for fibromyalgia and other disorders R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The ... 12/28/06 - 20060293389 - Process for producing injectable gabapentin compositions Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic ... 12/21/06 - 20060287392 - Gabapentin compositions The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed. ... 12/14/06 - 20060281816 - Pregabalin free of lactam and a process for preparation thereof The present invention encompasses Pregabalin substantially free of Lactam and a process for obtaining Pregabalin substantially free of Lactam comprising extracting an acidic mixture containing a complex of Pregabalin with a strong mineral acid, with a C3-8 alcohol; and combining the organic phase with an organic base. ... 12/07/06 - 20060276544 - Pregabalin free of isobutylglutaric acid and a process for preparation thereof A Pregabalin having a low level of 3-isobutylglutaric acid is provided. ... 12/07/06 - 20060276543 - Crystalline forms of pregabalin Crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.8, 18.4, 19.2, 20.7, and 23.7° 2θ±0.2° 2θ, methods for its preparation, its pharmaceutical compositions thereof, and methods for the preparation of crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.7, 15.4, 17.2, 18.2, ... 11/23/06 - 20060264509 - Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs ... 11/23/06 - 20060264508 - Modulation of ocular growth and myopia by gaba drugs Provided are methods and compositions for controlling postnatal ocular growth and the development of ocular errors in the maturing eye of a subject, comprising altering the refraction and/or growth of the maturing eye of a subject by administering to the eye a therapeutically effective amount of at least one GABA ... 11/02/06 - 20060247313 - Amino acid composition promoting collagen synthesis Herein are disclosed an excellent collagen synthesis-promoting amino acid composition that are characterized by containing specific amino acids at a specific ratio, more specifically, by containing 10-40 parts by weight of L-arginine and/or 10-40 parts by weight of L-glutamine, as well as 5-20 parts by weight of L-valine, 8-30 parts ... 11/02/06 - 20060247312 - Composition comprising free amino acids A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. A method of production of the composition; use of the composition in the manufacture of a medicament; ... 10/19/06 - 20060235079 - Process for the preparation of gabapentin form-ii The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-II via a novel intermediate Gabapentin hemisulphate hemihydrate with out forming Gabapentin Form-III by neutralizing the Gabapentin hemisulphate hemihydrate solution with a base at higher temperatures followed by cooling to yield Gabapentin Form II with ... 09/14/06 - 20060205817 - Method for preparing 4-hydroxyisoleucine diastereoisomers and enantiomers and derivatives thereof The invention concerns a method for preparing 4-hydroxyisoleucine diastereoisomers and enantiomers and derivatives thereof of general formula (I), characterized in that it consists in reducing an isoxazole derivative of formula (II) in conditions directly resulting in the derivatives of formula (I), or in obtaining at least a lactone of structure ... 08/17/06 - 20060183801 - Method of preventing or treating breast, prostate and/or cervical cancer with n, n-dimethylglycine The invention relates to a method of treating, inhibiting the metastasis of, or preventing cervical, breast or prostate cancer comprising administering to a patient an effective amount of N,N-dimethylglycine or a pharmaceutically acceptable salt thereof. ... 08/03/06 - 20060173078 - Method of treatment or prophylaxis of symptoms of herpes viral infection A method providing the treating or prophylaxis of one or more symptoms of viral infection. The method involving the administration of citrate and/or succinate salts. The present invention also encompasses the use of citrate and/or succinate salts for the treatment of prevention of lesions or blisters, or other symptoms of ... 07/27/06 - 20060167099 - Use of compositions that increase glutamate receptor activity in treatment of brain injury The present invention provides a method for treating a brain injury. This method comprises administering to a mammal afflicted with a brain injury a pharmaceutical composition therapeutically effective to increase glutamate receptor activity in the brain of said mammal. The pharmaceutical composition is to be administered after an acute postinjury ... 07/27/06 - 20060167098 - Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol The present invention concerns a method for the treatment and/or the prevention of diseases linked to the accumulation of triglycerides in tissues and blood comprising at least the step of administering to a human or non human animal in need thereof, as therapeutically active agent, an effective amount of (3-aminoisobutyric ... 07/20/06 - 20060160900 - Intrathecal gabapentin for treatment of pain Methods for treating pain by administering gabapentin to cerebrospinal fluid of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable pump having a reservoir for housing a composition, a catheter having a proximal portion coupled to the pump and having ... 07/20/06 - 20060160899 - Intrathecal gabapentin for treatment of epilepsy Methods for treating epilepsy by administering gabapentin to cerebrospinal fluid and brain tissue of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable device having a pump coupled to a reservoir for housing a composition, a catheter having a proximal ... 06/08/06 - 20060122272 - Stable gabapentin compositions Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions. ... 06/08/06 - 20060122271 - Stable gabapentin having ph within a controlled range A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3. ... 06/01/06 - 20060116426 - Inhibitor for perioperative blood sugar elevation An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation ... 05/18/06 - 20060106109 - Short term treatment for uterine disorder This invention is directed to a method and device for treating a female patient's uterine disorder by occluding one or both of the patient's uterine artery. The treatment embodying features of the invention basically involves occluding one or both of the patient's uterine arteries with an intravaginal device to form ... 05/11/06 - 20060100281 - Method of treating tinnitus and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6. ... 05/11/06 - 20060100280 - Cell growth regulator The present inventors examined cell growth of human colon cancer cell lines and breast cancer cell lines using L-2-phenylglycine, which is considered to be an amino acid transporter ATB0,+ inhibitor, as a test substance to reveal a concentration-dependent cell growth inhibitory effect. This result shows that inhibition of ATB0,+ activity ... 05/04/06 - 20060094785 - Use of amino acids for treatment of various conditions A method of treating a patient for a condition characterized by symptoms that can be alleviated by interfering with or supplementing the activity of endogenous ligands on the a2S subunit of a voltage gated calcium channel, said method comprising: administering to a patient experiencing the condition an amount of one ... 04/27/06 - 20060089412 - Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease There is provided a method of preventing or treating non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, which comprises administering a pharmaceutical composition comprising L-alanine as an active ingredient to a patient suffering from the disease. This pharmaceutical composition is safe and efficacious for prevention and/or therapeutic treatment of non-alcoholic fatty ... 03/23/06 - 20060063839 - Inhibitors of decrease in body temperature The present invention provides an inhibitor of decrease in body temperature which comprises at lease one kind of an amino acid(s) selected from the group consisting of valine, asparatic acid, glycine and cystein as an active substance. This inhibitor of decrease in body temperature can inhibit the decrease in body ... 03/16/06 - 20060058389 - Novel compounds that inhibit factor xa activity or a pharmaceutically acceptable salt, solvate, hydrate or pharmaceutically acceptable formulation thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thromboembolic conditions. ... 03/09/06 - 20060052454 - Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders A method of treating or preventing a subject's health problem that is related to an underlying disorder in the functioning of the metabolic system of the subject includes the step of administering a therapeutically effective dosage of glycine. For health problems associated with the subject's bones, cartilage or connective tissue, ... 03/02/06 - 20060047002 - Process for the preparation of 4,5-diamino shikimic acid derivatives R3, R4 are independent of each other H or an alkanoyl, with the proviso that not both R3 and R4 are H. 4,5-diamino shikimic acid derivatives of formula I, especially the (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester and its pharmaceutically acceptable additional salts are potent inhibitors of viral neuraminidase. ... 02/09/06 - 20060030624 - Anticancer agents based on prevention of protein prenylation Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. α-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be ... 01/26/06 - 20060020034 - Processes for the preparation of gabapentin The present invention relates to new processes for the preparation of gabapentin by the desilylation of a silylated gabapentin or by the silylation-desilylation of an acid addition salt of gabapentin with a silylating agent. ... 01/26/06 - 20060020033 - Method for treating dermatological viral infections A method for treating dermatological viral infections includes applying a photosensitizing agent to virally infected skin, allowing the virally infected skin to become photosensitive, and illuminating a beam of visible light onto the photosensitive skin to produce a photodynamic reaction substantially reducing the amount of viral infection to the skin. ... 01/26/06 - 20060020032 - Animal composition The present invention relates to a composition which delivers an amount of leucine sufficient to enhance the learning ability of an animal. The present invention also relates to a food supplement for enhancing the learning ability of an animal and to methods for enhancing such learning ability. ... 01/12/06 - 20060009523 - High concentration baclofen preparations Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. ... 01/05/06 - 20060004101 - Inhibitor for liver cancer onset and progress The present invention provides a prophylactic or therapeutic agent, a pharmaceutical composition and a health-promoting food, which are used for human or other animal for the inhibition of the onset or progress of liver cancer, namely, an inhibitor of the onset or progress of liver cancer, which contains isoleucine, leucine ... 12/22/05 - 20050282898 - Methods for the synthesis of milnacipran and congeners thereof One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods ... 12/01/05 - 20050267213 - Use of photodynamic therapy to enhance treatment with immuno-modulating agents Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy ... 11/24/05 - 20050261372 - Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C1-C6)alkyl, (C3-C6)alkenyl, 3-oxo(C5-C6)alkyl, 3-oxo(C4-C6)alken-2-yl, phenyl(C1-C6)alkyl, phenyl(C2-C6)alkenyl, gem-diphenyl(C1-C6)alkyl, gem-diphenyl(C2-C6)alkenyl, (C1-C6)alcanoyl, optionally N-substituted alanyl, optionally N,N′-disubstituted lysinoyl, phenyl(C1-C6)alkylydene or gem-diphenyl(C1-C6)alkylidene group, and of the pharmaceutically acceptable salts thereof, for preparation of medicaments intended for the treatment of CNS diseases due to reduced ... 11/10/05 - 20050250851 - Methods for treating neuropsychiatric disorders The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of ... 11/10/05 - 20050250850 - Amino acid composition promoting collagen synthesis Herein are disclosed an excellent collagen synthesis-promoting amino acid composition that are characterized by containing specific amino acids at a specific ratio, more specifically, by containing 10-40 parts by weight of L-arginine and/or 10-40 parts by weight of L-glutamine, as well as 5-20 parts by weight of L-valine, 8-30 parts ... 11/03/05 - 20050245613 - Use of gaba-b receptor positive modulators in gastro-intestinal disorders The invention relates to the use of a compound acting as positive allosteric modulator of GABAB receptors in the treatment of GERD, regurgitation, IBS, dyspepsia, postoperative complaints and conditions associated with visceral discomfort/pain. ... 10/27/05 - 20050239890 - Methods for decreasing detrusor muscle overactivity A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in ... 10/20/05 - 20050234128 - Process for preparing fluoroleucine alkyl esters This invention relates to a stereoselective preparation of fluoroleucine alkyl esters. ... 10/13/05 - 20050228049 - Methods for decreasing detrusor A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that ... 10/13/05 - 20050228048 - Stable eye drops containing latanoprost as the active ingredient The present invention provides a latanoprost ophthalmic solution which can be stored at room temperature and is excellent in stability. The ophthalmic solution according to the present invention is an ophthalmic solution comprising latanoprost, wherein latanoprost is stabilized to be stored at room temperature by at least one means selected ... 09/22/05 - 20050209332 - Gabapentin analogues and process thereof The present invention relates to compounds cis (Z) and trans (E) stereoisomers of 4-t-butylgabapentin of formula (11) and (12) and a process for the preparation of the said stereoisomers. ... 09/22/05 - 20050209331 - Method of treatment of skin A method for treating a region of skin. An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in the skin is applied to the region of skin. The photolabile compound generates a biologically active agent when in the skin and the ... 09/22/05 - 20050209330 - Method of treatment of skin A method for treating a region of skin. The method comprises applying 5-aminolevulinic acid (ALA) to the region of the skin and exposing the region to sunlight. ... 09/08/05 - 20050197399 - Method of augmenting the antitumor activity of anticancer agents A method for augmenting the antitumor activity of anti-cancer agents is provided. The method comprises administering to an individual an anti-cancer agent and a selenium compound. A method is also provided for inhibiting the growth of a tumor which has proven to be refractory to anticancer agents. The methods comprises ... 09/08/05 - 20050197398 - Therapeutic agent for hepatic disease Pharmaceutical compositions which contain isoleucine, leucine, valine, and alanine as active ingredients, are useful for treating liver diseases such as hepatitis, liver cirrhosis, liver cancer, and the like via maintenance and improvement of albumin level in blood. In preferred embodiments, the mass ratio of isoleucine:leucine:valine is 1:1.9 to 2.2:1.1 to ... 09/01/05 - 20050192353 - Treating or preventing restless legs syndrome using prodrugs of gaba analogs Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome. ... 08/25/05 - 20050187295 - Processes for the preparation of gabapentin The present invention relates to a process of preparing gabapentin from its hydrochloride salt by the use of alkylamine and choice of solvent. The resulting gabapentin can be isolated either as Form II or Form III, characterized by their spectra, by simply choosing an appropriate solvent in the process. ... 08/11/05 - 20050176827 - Compositions and methods for glycogen synthesis A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat ... 08/11/05 - 20050176826 - Use of asc-1 inhibitors to treat neurological and psychiatric disorders The present invention relates to the identification and use of compounds that are inhibitors of the alanine-serine-cysteine transporter 1 (asc-1). This includes an assay for the identification of compounds that are inhibitors of asc-1, as well as pharmaceutical compositions comprising these compounds. The invention also comprises a method for the ... 08/04/05 - 20050171203 - Pregabalin composition A chemically and physically stable, orally administrable aqueous pharmaceutical composition containing pregabalin is described. The liquid composition includes at least one preservative, at least one taste-masking agent, and an optional viscosity control agent. The liquid pharmaceutical composition has a pH of at least about 5.5 but not greater than about ... 07/21/05 - 20050159487 - Cyclic amino acids and derivatives thereof useful as pharmaceutical agents The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as ... 07/07/05 - 20050148669 - Amino acid esters as nutrient supplements and methods of use The present invention provides novel nutrient and food supplement amino acid ester compounds and compositions for human and animal consumption. ... 06/30/05 - 20050143466 - Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, ... 06/09/05 - 20050124695 - Developmental animal model of temporal lobe epilepsy Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the ... 06/02/05 - 20050119345 - 6-fluorobicyclo[3.1.0]hexane derivatives [wherein R1 and R2, which may be the same or different, each represent a hydroxyl group, a C1-10 alkoxy group, etc.; R3 represents a C1-10 acyl group, a C1-6 alkoxy-C1-6 acyl group, etc.; and R4 and R5, which may be the same or different, each represent a hydrogen atom, a ... ### FreshPatents.com Support |